Effects of high dose aleglitazar on renal function in patients with type 2 diabetes

International Journal of Cardiology

Volumn 151, Issue 2, 2011, Pages 136-142

  Herz, Matthias ^a   Gaspari, Flavio ^b   Perico, Norberto ^b   Viberti, Giancarlo ^c   Urbanowska, Teresa ^a   Rabbia, Michael ^d   Kirk, Dominika Wieczorek ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

Acute coronary syndrome; Cardiovascular risk; Diabetes; Peroxisome proliferator activated receptor

Indexed keywords

ALEGLITAZAR; CYSTATIN C; GLUTATHIONE TRANSFERASE ALPHA; N ACETYL BETA GLUCOSAMINIDASE; PIOGLITAZONE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERPHAGIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; OXAZOLES; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; THIOPHENES; YOUNG ADULT;

EID: 79956066099     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.037     Document Type: Article

References (28)

1. A. Bénardeau, J. Benz, and A. Binggeli Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes Bioorg Med Chem Lett 19 9 2009 2468 2473
2. R.R. Henry, A.M. Lincoff, S. Mudaliar, M. Rabbia, C. Chognot, and M. Herz Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 9684 2009 126 135
3. J. Yang, D. Zhang, J. Li, X. Zhang, F. Fan, and Y. Guan Role of PPARγ in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential Clin Sci (Lond) 116 1 2009 17 26
4. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 9500 2005 1849 1861
5. J. Lipscombe, G.F. Lewis, D. Cattran, and J.M. Bargman Deterioration in renal function associated with fibrate therapy Clin Nephrol 55 1 2001 39 44 (Pubitemid 32041781)
6. M. Elisaf Effects of fibrates on serum metabolic parameters Curr Med Res Opin 18 5 2002 269 276 (Pubitemid 35014543)
7. M.H. Davidson, A. Armani, J.M. McKenney, and T.A. Jacobson Safety considerations with fibrate therapy Am J Cardiol 99 6A 2007 3C 18C
8. J.C. Ansquer, R.N. Dalton, E. Caussé, D. Crimet, K. Le Malicot, and C. Foucher Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people Am J Kidney Dis 51 6 2008 904 913 (Pubitemid 351697561)
9. N. Broeders, C. Knoop, M. Antoine, C. Tielemans, and D. Abramowicz Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15 12 2000 1993 1999
10. V. Tsimihodimos, A. Kakafika, and M. Elisaf Fibrate treatment can increase serum creatinine levels Nephrol Dial Transplant 16 6 2001 1301 (Pubitemid 32547398)
11. F. Gaspari, N. Perico, and P. Ruggenenti Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate J Am Soc Nephrol 6 2 1995 257 263
12. E. Minetti, M. Cozzi, E. Biella, and F. Napoli Evaluation of a short protocol for the determination of para-aminohippurate and inulin plasma clearances J Nephrol 7 6 1994 342
13. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 1999 461 470 (Pubitemid 29135798)
14. N. Kamber, and T.M. Davis Tesaglitazar IDrugs 8 11 2005 927 935
15. H. Bays, J. McElhattan, and B.S. Bryzinski A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus Diab Vasc Dis Res 4 3 2007 181 193 (Pubitemid 47529208)
16. J.P. Wilding, I. Gause-Nilsson, and A. Persson Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes Diab Vasc Dis Res 4 3 2007 194 203 (Pubitemid 47529209)
17. B. Göke, I. Gause-Nilsson, and A. Persson The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes Diab Vasc Dis Res 4 3 2007 204 213 (Pubitemid 47529210)
18. R.E. Ratner, S. Parikh, and C. Tou Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes Diab Vasc Dis Res 4 3 2007 214 221 (Pubitemid 47529211)
19. A 24-week, randomised, parallel-group, multi-centre, open-label study of the renal effects of tesaglitazar in patients with type 2 diabetes mellitus. ARMOR (Analysing Renal Mechanisms of creatinine excretion in patients On tesaglitazaR). (Accessed December 17, 2009, at http://www. astrazenecaclinicaltrials.com/-mshost2715844/content/content/resources/media/ 2958892/4344444.)
20. C. Hottelart, N. El Esper, F. Rose, J.M. Achard, and A. Fournier Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 3 2002 536 541
21. V. Tsimihodimos, G. Miltiadous, E. Bairaktari, and M. Elisaf Possible mechanisms of the fibrate-induced increase in serum creatinine Clin Nephrol 57 5 2002 407 408
22. B.J. Ledwith, C.J. Pauley, L.K. Wagner, C.L. Rokos, D.W. Alberts, and S. Manam Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12, 13-myristate-type tumor promoters in immortalized mouse liver cells J Biol Chem 272 6 1997 3707 3714 (Pubitemid 27067016)
23. M.W. Wilson, L.T. Lay, C.K. Chow, H.H. Tai, L.W. Robertson, and H.P. Glauert Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid Arch Toxicol 69 7 1995 491 497
24. A. Keech, P. Drury, and T.M. Davis Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study [Abstract 983] Circulation 120 18-Meeting Abstracts 2009 S419 S420
25. S. Arima, K. Kohagura, and K. Takeuchi Biphasic vasodilator action of troglitazone on the renal microcirculation J Am Soc Nephrol 13 2 2002 342 349 (Pubitemid 34106275)
26. T. Roszer, and M. Ricote PPARs in the renal regulation of systemic blood pressure PPAR Research 2010 Article ID 698730, doi:10.1155/2010/698730.
27. A.J. Apperloo, D. de Zeeuw, and P.E. de Jong A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function Kidney Int 51 3 1997 793 797 (Pubitemid 27157964)
28. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150